Inhibition of miR-483–5p, anti-IGF-2 neutralizing antibodies, and small molecule tyrosine kinase inhibitors targeting IGF1R have demonstrated efficacy in limiting meningioma cell proliferation in vitro [58]. This evidence concerns the gene IGF1R and meningioma.